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                                   CHAPTER - 1
INTRODUCTION
Diabetes Mellitus complicates 2–20% of all pregnancies. Of this 90% is 
Gestational diabetes mellitus.
Gestational diabetes mellitus is defined as carbohydrate intolerance of 
variable severity with onset or first recognition during pregnancy regardless 
of whether or not insulin is used for treatment.
Hyperglycemia is associated with adverse outcomes of pregnancy in women 
with Gestational diabetes mellitus. The principal approach to glycaemic 
control in pregnant women with diabetes is dietary therapy and insulin 
administration has been standard therapy for dietary failures until recent 
years. Approximately 30 – 40 % of patients require pharmacological 
treatment. Antihyperglycaemic drugs were not used during pregnancy for 
fear of neonatal hypoglycaemia and foetal anomalies. This is based mainly 
on studies before the availability of drugs like Glibenclamide and Glipizide, 
which are in common use today. Studies have demonstrated that 
glibenclamide does not cross human placenta in appreciable quantities, in 
contrast to older sulfonylurea drugs and metformin. Insulin therapy has the 
disadvantages of patient discomfort, inconvenience of injections and expense 
there by potentially compromising compliance. 
On the basis of these findings and the relatively mild hyperglycaemia in most 
pregnant women with Gestational diabetes mellitus, Glibenclamide might be 
an alternative therapy in patients with Gestational diabetes mellitus.
CHAPTER – 2
REVIEW OF LITERATURE
HISTORY
Diabetes was described more than 2000 years ago. An ancient Hindu 
document by susruta in India in about 400 BC has described the Diabetic 
syndrome as characterized by a “honeyed urine”. The word Diabetes (to flow 
through) was coined by Greek physician Aretaus of Cappadocia in first 
century (150 AD) from the word siphon (sweet taste). The word mellitus 
(honeyed) added by John Rollo in 18th century. In 1674 Thomas Willis, a 
physician, anatomist and a professor of Natural Philosophy at oxford 
discovered by tasting that the urine of diabetic persons was “Wonderfully 
sweet as if imbued with honey or sugar”. Willis could not explain the 
chemical nature of this sweet substance. It was Mathew Dobson of 
Manchester, England who in 1776 demonstrated that diabetics actually 
excrete sugar in urine. It was John Rollo, Surgeon general of Royal artillery 
who first applied the discovery of glycosuria by Dobson to the quantitative 
metabolic study of diabetes. The entity gestational diabetes mellitus was 
firmly established in 1964 (O’Sullivan and Mahan).
It was Claude Bernard who studied the association between pancreas and 
diabetes. The name Insulin was christened by De Mayer (1909). In 1921 
Fredrick Banting and Charles Best with the help of chemist J B Collip 
succeeded in fulfilling all of the criteria for therapeutic active Insulin. The 
name insulin is derived from the Latin word “INSULA” which means “AN 
ISLAND” denoting the beta cells of Islets of Langerhans. Insulin was 
isolated in crystalline form by Abet in 1938. Sanger elucidated the chemical 
structure of insulin in 1960. Insulin molecules were fully synthesized in lab 
by 1996.
In the pre-insulin era pregnancy in the diabetic women cannot even be 
dreamt of. The maternal mortality ranged from 6 to 45% before 1921. Even 
after the introduction of insulin in the treatment of diabetes in pregnancy the 
perinatal mortality remained near 30%. During 1940 to 1970 the perinatal 
mortality was brought down to 20% by comprehensive team approach by 
obstetrician, diabetologist, neonatalogist and anaesthetist. With the 
introduction of AN foetal surveillance between 1971 to 1976 the perinatal 
mortality was reduced to 12%.
OHA IN PREGNANCY
The Hypoglycaemic action of Sulfonylurea was an accidental discovery 
during the end of world war-II, while treating typhoid fever. The first OHA 
suitable for clinical use, the Sulfonylureas developed by Auguste Loubatieres 
in early 1940’s. In 1961 Endean and Smith thought that the treatment of 
diabetes with oral agents had been a tremendous step forward and advocated 
its use in diabetic women. Jackson et al started a storm with their report of 42 
women who received tolbutamide or chlorpropamide during pregnancy. He 
concluded that chlorpropamide in a dosage of 500 mg /day appeared to be 
associated with a high perinatal mortality, although it might be safer at a 
lower dosage and that tolbutamide appeared to be safe. This high perinatal 
mortality may be due to poor diabetic control rather than due to congenital 
anomalies.
Langer et al 2002 stated OHA in pregnancy – “Their time has come”. 
(Journal of maternal, foetal and Neonatal medicine – 2002). Use of 
Glibenclamide in pregnancy is considered to be safe in pregnancy because of 
insignificant placental transfer of it in humans by using in vitro models such 
as placental perfusion models, leading to successful clinical trial of 
glibenclamide (Garcia –Bournissen, clinical pharmacokinectics-2003). 
Recently Gabbe and Graves stated, “an alternative to insulin therapy is the 
oral hypoglycaemic agent – glyburide”. (AJOG – 2005).
There are limited data on exposure of OHA’S to the infant via breast milk, 
and the serious effect of neonatal hypoglycaemia, the safest recommendation 
is not to breast feed the infant while taking OHA. (AU Merlob P levitt O 
Stahl B-SO Pediatric drugs – 2002) but glibenclamide is not secreted in 
breast milk (Diabetes care Feb-2006).
Classification of oral Hypoglycamic agents
Sulfonylureas Biguanides     Glucosidase  Thiazolidinediones
- Phenformin      inhibitors           - Troglitazone
- Metformin    - Acarbose           - Pioglitazone
I generation SUS            II generation SUS
-  Tolbutamide     -  Glibenclamide
-  Chlorpropamide     -  Glipizide
-  Acetohexamide   -  Gliclazide
-  Tolazamide
GLIBENCLAMIDE – PHARMACOLOGY
It was the first “second generation” Sulfonylurea to be introduced in clinical 
practice and it is the most potent’
CHEMICAL STRUCTURE OF GLIBEMCLAMIDE
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MECHANISM OF ACTION
1. Stimulation of insulin release from the pancreas –single dose provokes brisk 
release of insulin from pancreas. Glibenclamide acts on the sulfonylurea 
receptors on the pancreatic beta cell membrane – causes depolarization by 
reducing conductance of ATP sensitive potassium channels. This enchances 
calcium influx – degranulation. The rate of insulin secretion at any glucose 
concentration is increased.
2. Reduction of glucagon levels.
3. Increasing somatostatin release.
4. Hepatic degradation of insulin is slowed.
5. It has a extrapancreatic action. It increases binding of insulin to target tissues 
and receptors.
PHARMACOKINETICS
Glibenclamide when given orally is absorbed well but slowly than the 
micronised form.  Although concomitant food intake does not seem to delay 
the absorption  its efficacy is increased if given before food. It has very low 
volume of distribution (0.2-0.42/Kg) and it is very extensively bound to 
albumin (90%-95%). Glibenclamide is completely metabolized mainly by 
oxidation to two hydroxylated metabolites both of which have glucose 
reducing activity. About half of a given dose of glibenclamide is eliminated 
by renal excretion of metabolites and a significant portion is excreted through 
the bile. Although renal insufficiency does not alter the elimination rate there 
is risk of hypoglycaemia. This is because renal insufficiency is associated 
with reduced drug binding to albumin in addition renal impairment may lead 
to accumulation of polar, active metabolites. It has relatively short half life 
(4-9 hrs). There is insignificant transfer of glibenclamide through the human 
placenta due to its property of high plasma protein binding and short half life. 
Moreover glibenclamide is a substrate for P-glycoprotein which is extruding 
pump in the placenta and inhibits it, thus preventing transplacental transfer of 
the drug in humans. Usual dose is 1.75 – 14.0 mg (micronised) or 2.5 – 20.0 
mg (non-micronised) per day.
The main concern about glibenclamide is its drug interactions. 
Hypoglycaemia, Nausea, Vomiting, diarrhoea, Hypersensitivity reactions are 
some of the adverse effects of glibenclamide. Incidence of adverse effects is 
quite low (3-7 %). 
SCREENING FOR GDM 
Screening of GDM should be universal as GDM is mostly asymptomatic. In 
a study by Hughes et al 1995 found that selective screening would have 
failed to detect 43 % of gestational diabetes mellitus. 28 % of them would 
have required Insulin. 
O’SULLIVAN’S ORAL GLUCOSE CHALLENGE TEST [OGCT]
It is otherwise known as universal screening test of O’Sullivan. This consists 
of giving a 50 gm glucose load irrespective of the patient’s feeding state and 
estimating plasma glucose after 1 hour and a value of > 140 mgm / 100 ml is 
taken as the cutoff. In 1990 Chicago workshop conference on gestational 
diabetes recommended that all pregnant women should be screened 
[Universal Screening] using a 50 gms. Oral glucose challenge test between 
24 and 28 weeks without regard to the time of day or last meal and that a 
plasma value at 1 hour exceeding 140 mgm/dl be used as cut-off for 
performing the diagnostic 100 gms 3 hrs oral glucose tolerance tests.
Sacks and Colleague (1976) studied on the reproducibility of this standard 
test and concluded that this reproducibility is adequate. This procedure 
involves the patient waiting for 1 hour following glucose ingestion and 
positive screenee have to have a second glucose load for diagnosis and it is 
also costly.
O’SULLIVAN& MAHAN’S ORAL GLUCOSE TOLERANCE TEST 
[OGTT]
This test serves as the Gold standard for the diagnosis of gestational diabetes 
mellitus. In O’Sullivan’s studies, whole blood was tested using the Somogyi 
– Nelson method for measuring reducing substances. Plasma Glucose values 
have been shown to be 14% higher than those in whole blood obtained from 
the same sample using the same assay method. Hence, NDDG adopted 
O’Sullivan’s values to plasma glucose. Later NDDG reinterpreted 
O’Sullivan’s data for glucose oxidase method on plasma by increasing 
O’Sullivan criteria by 15%. This criteria reaffirmed by American Diabetic 
Association in 1985, stated that the glucose oxidase method is specific for 
glucose and generally result in 5 mg / dl decrease in measured values in the 
range of glucose concentration (Carpenter and coustan).
The upper limits for normal (threshold) were selected statistically and 
defined as two standard deviation (SD) above the mean for each of the four 
glucose values in 3hr test. The gestational diabetes mellitus is diagnosed 
when two values meet or exceed the threshold. If one value is abnormal, it is 
called single value abnormality and if the 2hr value is above 120mg % it is 
diagnosed as Impaired Gestational Glucose Tolerance.
Patient in high-risk group should have a glucose tolerance test done, as early 
in pregnancy as possible and if they have a normal glucose tolerance curve, 
the test should be repeated at 28 weeks gestation. At this gestational age, 
diabetogenic effect of pregnancy is near its peak and the chances of a positive 
result from glucose tolerance test are high.
Because O’Sullivan’s original criteria were developed from statistical model 
it remains uncertain whether even the most accurate transliteration of them to 
modern testing method is relevant.
CRITERIA FOR DIAGNOSIS
Time
O’Sullivan 
(48) and 
Mahan
NDDG (49) 
Adaptation
Carpenter and (50) 
Coustan 
Adaptation
Fasting 90 105 95
1 hour 165 190 180
2 hour 145 165 155
3 hour 125 145 140
75 GM ORAL GLUCOSE TOLERANCE TEST
1. Gestational diabetes mellitus diagnosis based on 2 hr 75 gm oral glucose 
tolerance test defined by either WHO or ADA predicts adverse 
pregnancy outcome.
2.    The criteria recommended by WHO is simple and cost effective and 
practiced by many centers.
3.  Further assuming that effective treatment is available, WHO criteria of 2 
hr plasma glucose greater than or equal to 140mg/dl identifying a large 
number of cases may have a greater potential for prevention.
4. One step procedure of WHO (2 hr PPG greater than or equal to 140 
mg/dl) serves dual purpose of both screening and diagnosis.
Seshiah et al stated that diagnosis of GDM by OGTT based on initial glucose 
challenge test screening leaves 21.5% undiagnosed. The two step procedure. 
Glucose challenge test followed by glucose tolerance test is not practical, as 
patients have to visit the clinic at least twice. Hence glucose challenge test 
with 75 gm of oral glucose load and diagnosing GDM if the 2 hr plasma 
glucose is greater than or equal to 140mg/dl as recommended by WHO 
would be more practical. (The journal of obstetrics and gynecology of India 
2005).
GLYCOSYLATED HAEMOGLOBIN
Second generation tests came into vogue since 1970’s and they had the 
advantage of high lighting on past glycaemic control. Glycosylated 
Haemoglobin was used as a screening test during 1970’s. The chemical 
reaction referred as glycation describes the linkage between a reducing sugar 
and a receptive amino acid. Mailard first described this in relation to food 
protein in 1912. Its possible relevance to clinical diabetes mellitus was 
recognized in 1962 when Huisman and Dozy observed that HbA1, which is 
the glycosylated fraction of glycosylated Haemoglobin, was increased in 
diabetics. In the diabetes mellitus the level of HbA1c would be proportional 
to the integrated blood glucose levels in the previous 7-8 weeks period 
approximating to the half – life of the average red blood cell shown by 
Gabbet et al in 1977.
Estimation of HbA1C is the measure of average and cumulative control of 
glycaemia of previous two to three months. It may be useful only in the 
retrospective documentation of GDM.
GDM however may not present with the constant elevation of blood glucose 
level as in non-pregnant state. Gravid women with GDM have low fasting 
blood glucose concentration, increased erythropoesis, younger RBCs, less 
glycated Hb., and fluctuating blood glucose level due to rapid change in the 
hormonal milieu. Hence as the measure of chronic hyperglycemia, HbA1c 
may not be so effective in the diagnosis of gestational diabetes mellitus.
Shah et al. measured HbA1c using exchange chromatography and applied 
NDDG criteria for gestational diabetes mellitus in a group of patients with 
risk factors. In the risk group, HbA1c level > 8.8% taken as abnormal. The 
results showed 27 % sensitivity for glycated Hb in the identification of 
gestational diabetes mellitus, these data do not support the use of HbA1c as a 
screening test for gestational diabetes mellitus.
It cannot be used for day-to-day adjustment of control [Irwin] and it cannot 
register hypoglycemia [Irwin]. It has poor sensitivity at lower blood glucose 
levels and it is not discriminative enough to differentiate between mean 
blood glucose of 90 and 135-mgm %. Hence not very useful in monitoring 
the control of gestational diabetes mellitus [Donald R Couston]. It can 
supplement but not replace blood glucose as accurately as in non-pregnant 
state. [Gam Su H.R]. Hyperglycaemia that affects HbA1c needs to be long 
standing while the hyperglycaemia that affects pregnancy develops in second 
trimester (Jovanoic et al). It is expensive and the results are disappointing 
(Oats et al  1987). HbA1c is most useful in pre-pregnancy clinic for 
counseling and also to predict foetal outcome.
The other glycosylated plasma proteins have the potential, as markers for 
gestational diabetes mellitus. Among them the glycosylated albumin has a 
shorter half-life than that of HbA1c and may be more effective in identifying 
women with an acute rise in mean daily blood glucose.
METABOLIC CHANGES IN NORMAL PREGNANCY 
The fuel metabolism during normal pregnancy is characterized by 
 Facilitated insulin action during the first half of pregnancy and 
 Diabetogenic stress during the second half of pregnancy.
EARLY WEEKS OF GESTATION
In the early weeks of gestation certain hormonal changes occur.
 Increase in fasting insulin concentration 
 Increase in glucose stimulated insulin release which reaches a peak at 
18-20weeks.
 Increase in serum levels of estrogen and progesterone which induces beta 
cell hyperplasia.
During the earlier weeks of gestation (before 20weeks) foetal  requirements 
for glucose is minimal.Hence in the normal pregnancy steroid stimulated 
insulin secretion can promote increased peripheral utilization of glucose.
Excess of glucose available in the fed state is converted to fatty acids and 
stored in adipose tissue and glucose carbon is used for protein synthesis. This 
is the anabolic phase of pregnancy when the mother stores energy in the form 
of tissue glycogen and fat stores.
By the mid and late trimester accelerated maternal insulin and enhanced 
peripheral  utilization of glucose leads to hypoglycaemia in fasted stated. 
This hypoglycaemia will lower the insulin secretion and enchances the 
hydrolysis of fat for release of fatty acids as alternate fuels. These net effect 
is called “Accelerated starvation” characterized by hypoglycaemia 
,hyperketonemia  and protein catabolism.
CARBOHYDRATE METABOLISM IN EARLY PREGNANCY (TO 20 
WEEKS)
Hormonal 
alteration Effect
Metabolic 
Change
      Estrogen and
      Progesterone
                 
 B-cell Hyperplasia 
and
      Insulin Secretion
     Tissue Glycogen storage
     Hepatic glucose 
production
     Peripheral utilization of 
glucose
     Fasting Plasma glucose
     Anabolic
     Due to sex 
steroids
               +
     Hyper 
insulinemia
LATER WEEKS OF GESTATION 
In the later part of pregnancy (from 20 weeks) foetal growth is much more 
rapid and there is increased nutrient flow across the placenta. The foetus 
competes with the mother for circulating glucose supplies. The insulin 
resistance and anti-insulin hormones helps to maintain glucose concentration 
and adequate glucose supply to the foetus. Thus glucose in the maternal 
circulation is diverted to the foetus.
The mechanism behind this altered metabolism is due to counter insulin 
hormones elaborated by the placenta. These are as follows.
1. Human chorionic somatomammotrophin (HPL) is the major peptide 
elaborated by the placenta. It has insulinotrophic and lipolytic properties. 
HPL inhibits glucose utilization by the mother and promotes glucose 
transfer to the foetus, thus maintaining the balance of accelerated foetal 
growth.
2. Placental insulinase and insulin antibodies may play a role as counter 
insulins.
3. In addition there is elevated levels of prolactin, Cortisol and glucagon 
concentration in late pregnancy which also confers insulin resistance.
These events occur in the catabolic phase of pregnancy. Due to lipolytic 
action of HPL the mother uses fat as alternative fuel diverting glucose for 
foetal utilization. During the fasted state amount of fat are drawn from 
adipose tissue store. This accelerated fat metabolism during fasted state leads 
to ketoacidosis Hence pregnant women are strictly instructed not to be in a 
fasted state.
CARBOHYDRATE METABOLISM IN LATE PREGNANCY
Hormonal 
alteration Effect
Metabolic 
Change
      H C S “Diabetogenic” Facilitated 
     
      Prolactin
      
      Bound and free 
cortisol
   Glucose tolerance Insulin 
resistance
     Hepatic glucose stores
     Hepatic glucose production
Anabolism during 
feeding
Accelerated 
starvation during 
fasting
Ensures glucose and 
AA to fetus.
ALTERED METABOLISM IN DIABETIC PREGNANCY
The transport of maternal fuel to the foetus requires normal placental 
intermediary metabolism and normal supply of substrates. Because diabetes 
may result in markedly abnormal concentrations of maternal glucose, fatty 
acids, triglycerides and amino acids, these may get transported to the foetus. 
Unlike the foetus of early gestation, the foetus of the late gestation is well 
equipped to synthesise and replace insulin from its pancreas and protect itself 
against brunt of abnormal fuel mixture, thereby normalizing blood sugar in 
circulation but in the process resulting in hyperinsulinemia of the foetus and 
due to its anabolic action causes macrosomia and associated complications.
MODIFIED PEDERSEN HYPOTHESIS
  MOTHER        FETUS  NEONATE       ADOLESCENT
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  Plasma Glucose                       MIXED NUTRIENTS                      IGT
   Amino Acids                                                                             DIABETES 
   Lipids
Gestational carbohydrate intolerance is asymptomatic. The subjects destined 
to develop gestational diabetes mellitus have limited pancreatic insulin 
reserve and reduced insulin sensitivity. The stress of pregnancy due to 
counter insulin hormones overwhelms the insulin reserves hence in the 
plasma, levels of all classes of fuels – aminoacids, fatty acids and glucose are 
elevated which are delivered to the foetus. This change is seen more during 
the latter half of pregnancy when counter insulin factors and insulin 
resistance is experienced. The foetal transportation of abnormal fuels result in 
hyperinsulinemia and the resultant macrosomia. Thus macrosomia and 
associated risk factors like prematurity, traumatic delivery, RDS, neonatal 
hypoglycaemia, hypocalcaemia, hyperbilirubinemia  become the major 
concern for the subjects with gestational diabetes.
FREINKELS FUEL MEDIATED TERATOGENESIS
Pre Pregnancy
Congenital Malformations
Behavioural Changes
Anthropometric Changes
I Trimester II Trimester III Trimester
EFFECTS OF GDM ON THE MOTHER AND THE FOETUS
ON THE MOTHER
• Pre-eclampsia and pregnancy induced hypertension is seen in 13.7% in 
gestational diabetes. Combs et al and Rosenn et al reported a significant 
association between poor glycaemic control and pre-eclampsia or pregnancy 
induced hypertension. The incidence of chronic hyperetension is 2.5% 
among gestational diabetes.
• Overall incidence of ketocidosis is 0.7% especially following beta agonist 
therapy. Kilvert et. Al; reported one case of diabetic ketoacidosis in 150 
cases of gestational diabetes mellitus. Diabetic ketoacidosis is preventable 
and the prevention can be accomplished with optimal gycaemic control.
• The incidence of Hydraminos ranges from 2.0 to 2.1% in gestational 
diabetes mellitus and it is about 20% to 30% in overt diabetics. Most infants 
of hydramniotic diabetic pregnancy are structurally normal, associated with 
increased incindence of preterm labour and premature rupture of membrane.
• Pyelonephriris  was  reported  in  1.2% of  gestational  diabetes  mellitus  and 
3.6% overt diabetes. There is no difference in incidence of Pyelonephritis in 
gestational diabetes mellitus and control groups.
• Preterm  labour  complicated  8.1%  of  gestational  diabetes.  There  is  a 
significant  correlation  between  preterm  labour  and  uro-genital  infection. 
(Candida  and  Trichomoniasis).  Molsted  and  Pederson  speculated  that, 
hormonal  differences  increased  the  frequency  of  preterm labour  in  non-
diabetic women.
• The incidence of primary caesarian section among GDM ranged from 13.4% 
to  18.4%and  repeat  section  in  GDM  is  around  16.5%.  The  increased 
incidence nowadays may be due to quick option for caeserean section, when 
there is least problem.
ON THE  FOETUS
• Hypoglycaemia is one of the common causes of perinatal morbidity. It is 
defined  as  blood  sugar  level  less  than  35  mg  %.  About50%of  the 
hypoglycemic  babies  may  remain  asymptomatic.  The  factor  mainly 
protective against foetal hypoglycemia is the optional control of maternal 
hyperglycemia especially during the third trimster and during labour. It has 
been shown that a mean maternal plasma glucose>105 mg/dl during the last 
four hours of labour in a diabetic mother leads to an higher incidence of 
neonatal hypoglycemia. 
• About  25%  of  the  infant  of  diabetic  mothers  may  present  with  serum 
calcium  of  <7  mg/dl  and  this  may  remain  mostly  asymptomatic  and  is 
usually detectable during the 2nd and 3rd day of birth. Hypomagnesemia may 
coexist and may require correction.
• Respiratory distress syndrome [RDS] occurs in about 5% of the infant of 
diabetic mothers and it is seen equally in gestational diabetes mellitus. Again 
a strict glycamic control reduces the incidence of RDS.
• Polycythemia  is  relatively  common  in  infant  of  diabetic  mother.  The 
hyperviscosity due to Polycythemia may induce congestive heart failure and 
vascular  thrombosis  accounting  for  the  increased  risk  of  renal  vein 
thrombosis in these infants.
• Hyperbilirubinemia, the common abnormality is due to increased bilirubin, 
production  and  decreased  life  span  of  the  RBCs  with  glycosylated  cell 
membranes.  Hepatic  conjugation of  bilirubin may be impaired due to  an 
immature liver.
FOETAL  PROBLEMS  ASSOCIATED  WITH  MATERNAL 
HYPERGLYCEMIA
First Trimester Second Trimester Third Trimester
Malformations
Growth retardation
Foetal wastage
Hypertrophy
Cardiomyopathy
Polyhydraminos      
Placental insufficiency
Pre-eclampsia
Foetal loss 
Low IQ
Hypoglycemia
Hypocalcaemia 
Hyperbilirubinemia
Respiratory –distress
Syndrome
Macrosomia
Hypomagnesemia 
Intrauterine death
FOETAL HYPERINSULISM
Foetal hyperinsulism in the foetus is called Diabetic Foetopathy.According to 
Pedersen hypothesis; foetal hyperinsulinism is the major cause for adverse 
neonatal outcome. Insulin level in the cord blood of < 20microU /ml were 
considered normal. Neonates with cord blood insulin levels >20microU/ ml 
represents a continuum of increasing diabetogenic fetopathy. Neonates with 
cord blood insulin < 20microU/ml as metabolically healthy, those with 20 –
50 microU/ml as having mild fetopathy, and those with >50microU/ml as 
having marked fetopathy (Early Hum Dev 1998 July).
Hence based on the above data this study was designed to screen pregnant 
women universally for GDM using 75 g OGTT. Of the diagnosed patients 
treatment with Insulin or glibenclamide was assigned randomly according to 
treatment protocol. HbA1c measured in all cases. They were followed till 
confinement and pregnancy outcome recorded.
CHAPTER - 3
AIM OF STUDY
To evaluate the safety and efficacy of Glibenclamide in comparison with 
Insulin for the treatment of Gestational diabetes mellitus in Indian 
population.
The Primary end point is to attain adequate glycaemic control.
Secondary end point is maternal and neonal outcome.
CHAPTER – 4
MATERIALS AND METHODS
The study “Comparison of Insulin and Glibenclamide in gestational diabetes 
mellitus” carried out in Govt RSRM Lying –in Hospital during the period 
from March 2005 to February 2006 with the concurrence of the ethical 
committee.
About 250 patients attending the antenatal clinic were included in screening 
for Gestational diabetes mellitus. The patients were selected randomly and 
belonged to gestational age between 11 to 33 weeks. At the first visit the 
patients were counseled for screening and asked to come after three days of 
unrestricted diet in a fasting state (8-10 hrs of overnight fasting) for a 75 gm 
oral glucose tolerance test.
Two samples of about 2cc blood were taken from each patient in fasting and 
two hours after a load of 75 gm of glucose in 200 ml of water. These samples 
were analysed by a semi automatic analyzer in the laboratory.
Patients were diagnosed as Gestational diabetes mellitus if fasting plasma 
glucose more than or equal to 95 mg /dl and or 2 hr PPGmore than or equal 
to 140 mg /dl. Among the 250 patients 35 had GDM according to the above 
criteria.
Out of these, 5 patients did not give consent to get included in the study. In 
the remaining 30 patients, 15 patients were put on Insulin therapy and 15 
patients were put on tablet Glibenclamide after getting an informed from the 
patient explaining the nature of the study. These women were randomly 
assigned to receive Insulin or Glibenclamide according to the treatment 
protocol. At the institution of treatment a detailed obstetric, family history 
and thorough clinical examination done. The incidence of GDM in the study 
was   14 %.
All the pregnant women included in the study were advised standard 
nutritional instruction for three meals and three snacks daily. Adherence to 
the dietary regimen was evaluated and reinforced at each visits to the clinic. 
The diet was designed to provide 25 kcal/kg of body weight for the obese 
women (BMI>27) and 35 kcal/kg (BMI<27) for the non-obese women with 
40-45 % of the calories from carbohydrate.
In the women assigned to receive Insulin, it is started at a lower dose of 
6units and a maximum of 55 units was used in the study.  The dose was 
adjusted according to the glycaemic status. In the glibenclamide group the 
starting was 0.625 mg orally, gradually increasing the dose and a maximum 
of 2.5 mg was used in the study to achieve adequate glycaemic control. The 
patients were instructed to come every 15 days for glycaemic profile. The 
aim was to keep fasting plasma glucose below 90 mg/dl and postprandial 
plasma glucose below 120 mg/dl and mean plasma glucose kept at 105 mg/dl 
measured at any time of the day. HbA1c was measured at the start of 
treatment and once again after delivery of baby. At each visit the patient 
undergoes detailed general and obstetric examination
Gestational age was determined on the basis of menstrual history and early 
USG if available. Ultrasound performed at 22, 28, 32 and 36 weeks to rule 
out macrosomia.
At delivery the neonatal team evaluated all neonates. Macrosomia is defined 
as birth weight greater than or equal to 3.5 kg. Neonate blood sugar and cord 
blood insulin level analyzed. Hypoglycaemia is defined  as plasma glucose of 
the neonate below 35 mg /dl. Cord blood insulin is considered to be abnormal 
if it is more than 20 mIu /ml. Serum bilirubin was measured in babies when 
there was clinical evidence of jaundice and the babies were given 
phototherapy as needed.
INCLUSION CRITERIA
Women with gestational age between 11-33 weeks and who were willing to 
deliver at RSRM hospital
EXCLUSION CRITERIA
1. Women with gestational age less than 11 weeks and more than 33 weeks.
2. Women not willing to have their delivery at RSRM.
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RESULTS
About 250 AN women attending the AN clinic were screened for GDM 
randomly with 75 gm OGTT. They were diagnosed as GDM if fasting 
plasma glucose more than or equal to 95 mg /dl and or 2 hr post glucose 
more than or equal to 140 mg /dl. 15 patients were put on insulin and 15 
patients on glibenclamide according to treatment protocol. 2 patients were 
lost in followup in the glibenclamide group.
The demographic details were summarized in the table-I
TABLE - I
Group-I 
(Insulin) (N=15)
Group-II 
(Glibenclamide) 
(N=15)
Age 27.87 ± 5.0 24.7 ± 3.6
Pre-pregnancy wt 59.3 ± 11.5 49.9 ± 10.9
BMI 25.2 ± 4.6 21.8 ± 3.54
GA at entry into 
study
24.3 ± 5.23 23.5 ± 8.43
The demographic profile was comparable in both insulin and glibenclamide 
group.
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The gravidity distribution is given in table II
TABLE - II
Gravidity Group-I (Insulin) (N=15)
Group-II 
(Glibenclamide) 
(N=15)
Primi 8 (53.3 %) 8 (53.3 %)
Multi 7 (46.6 %) 7 (46.6 %)
There was equal distribution of primi and multi gravida in both insulin 
and glibenclamide group.
GRAVIDITY DISTRIBUTION
Insulin Group
53.3
46.6
Primi Multi
Glibenclamide Group
53.3
46.6
Primi Multi
Table-III shows distribution of patient with positive family history of 
diabetes and with bad obstetric History.
TABLE - III
Group-I 
(Insulin) (N=15)
Group-II 
(Glibenclamide) 
(N=15)
BOH 5 (33.3 %) 6 (40.0 %)
Positive family 
history
6 (40.0 %) 5 (33.3 %)
There was almost equal distribution of antenatal women with bad obstetric 
history and positive family history of diabetes in both insulin and 
glibenclamide group.
BOH & FAMILY HISTORY
Insulin Group
33.3
40
26.7
BOH Positive family History No Family History or No BOH
Glibenclamide Group
40
33.3
26.7
BOH Positive family History No Family History or No BOH
The screening plasma sugar values are summarized in the following table-IV
TABLE – IV
Group-I 
(Insulin) 
(N=15)
Group-II 
(Glibenclamide) 
(N=15)
‘P’ 
Value
Fasting Plasma 
Glucose 90.07 ± 22.1 75.73 ± 23 0.072
2 hr Post 
Glucose Plasma 
Glucose
177.8 ± 28.4 173.2 ± 25.35 0.65
 
There was 6 patients in insulin group and 2 patients in the glibenclamide 
group with fasting plasma glucose more than or equal to 95 mg / dl (fasting 
hyperglycaemia).
The screened patients were selected randomly for treatment with insulin or 
glibenclamide.. The glycaemic status of the women during the course of 
treatment is summarized in table-V.
TABLE – V
Group-I 
(Insulin) 
(N=15)
Group-II 
(Glibenclamide) 
(N=15)
‘P’ 
Value
Fasting Plasma 
Glucose 68.53 ± 13.5 62.27 ± 7 0.96
2 hr Post 98.6 ± 10.1 95.9 ± 6.1 0.44
Prandial Plasma 
Glucose
 The aim of treatment was to keep fasting plasma glucose below 90 
mg / dl and Post Prandial plasma glucose below 120 mg / dl and mean 
plasma glucose 105 mg / dl measured at any time of the day. Adequate 
glycaemic control was achieved in both insulin and glibenclamide group. A 
maximum dose of 2.5 mg of glibenclamide was needed in the study to 
achieve desired glycaemic level.  
Pre-treatment HbA1C as compared with post –treatment HbA1c (Table-VI).
TABLE - VI
Group-I 
(Insulin) 
(N=15)
Group-II 
(Glibenclamid
e) (N=15)
‘P’ 
Value
Pre – Treatment 
HbA1c 5.5 ± 0.89 5.1 ± 0.46 0.45
Post Treatment 
HbA1c
5.5±0.56 5.38±0.31 0.60
Both pre-treatment and Post –treatment HbA1c values were similar in both 
the treatment groups.The values were not significant and it also indicates 
HbA1c may not be very useful in GDM because of lesser degree of 
hypoglycaemia in GDM.
The patients were followed upto delivery and the Pregnancy outcome details 
recorded. The pregnancy outcome details were illustrated in table-VII. 
TABLE - VII, NEONATAL OUT COME
Group-I 
(Insulin)
(N = 15)
Group-II 
(Glibenclamid
e)  (N = 13)
‘P’ Value
Birth weight 2.88 ± 0.45 2.56 ± 0.84 0.23
New born Pla 
sma Glucose 72.87 ± 28.4 69.1 ± 14.45 0.78
Cord Blood 
Insulin 5.24 ± 2.7 4.88 ± 4.9 0.89
NICU 
Admission for 
photo-
theraphy
3(20%) 1(7.7%) -
 
TABLE - VIII, MATERNAL OUT COME
Group-I
(Insulin)  (N = 
15)
Group-II 
(Glibenclamide)  (N = 
13)
PIH 2 (13.3%) 1 (7.7%)
Polyhydraminos Nil Nil
Retinopathy Nil Nil
Caesarean 
Deliveries 10 (66.7%) 9 (69.2%)
 
The pregnancy outcome were similar in both the groups. Except one patient 
in glibenclamide group had second trimester abortion probably due to late 
detection and one patient in insulin group delivered a macrosomic baby (3.5 
kg). Hypoglycaemia was not detected in any of the babies in both the groups. 
Three neonates in insulin group and one neonate in glibenclamide group 
needed phototheraphy for clinical jaundice for 1 to 2 days. Cord blood 
insulin was in normal range in both the groups indicating absence of 
hyperinsulinemia. There was no case of congenital anomaly in the study. 
Post delivery HbA1c was normal in both groups indicating good glycaemic 
control during treatment.  Incidence of PIH and cesarean delivery was same 
in insulin and glibenclamide group.
CEASEREAN Vs VAGINAL
Insulin Group
66.7
33.3
Ceaserean Vaginal
Glibenclamide Group
69.2
30.8
Ceaserean Vaginal
Fasting and post prandial plasma glucose was taken in all patients before 
discharge from the hospital. This is summarized in table-VII.
TABLE - IX
Group-I 
(Insulin)
Group-II 
(Glibenclamide)
‘P’ 
Value
Fasting Plasma 
Glucose 68.07 ± 16.9 66.27 ± 7.0 0.53
2 hr Post 
Prandial Plasma 
Glucose 
95.47 ± 10.97 95.9 ± 6.1 0.89
 
Post delivery fasting and post prandial plasma glucose was normal in all 
patients.There were no significant differences between the two groups in any 
of the characteristics depicted in all the tables by student’s t- test, suggesting 
both the drugs are equally effective.  
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DISCUSSION
The present study comparing the effects of insulin and glibenclamide in 
GDM had 15 patients in insulin group and 15 patients in glibenclamide 
group. 2 patients in glibenclamide group were lost in the follow up.
The demographic details in the present study compared with the study done 
by Langer et al comparing 203 patients in insulin group and 201 patients in 
glibenclamide group.
TABLE-I  DEMOGRAPHIC PROFILE
Insulin Group Glibenclamide Group
Age BMI > 27
GA at 
Entry Age
BMI 
> 27
GA at 
Entry
Pres
ent 
Stud
y
27.87±
5.0
4 
(26.6
%)
24.3±5
.23
24.70±
3.6
1 
(6.67
%)
23.5±8.
43
Lan
ger 
et al 
Stud
y
30.0±6
.0
132 
(65%
)
25.0±7
.0
29.0±7
.0
141 
(70%
)
24.0±7.
0
The age distribution in present study is slightly lower but comparable with 
Langer et al one. The slightly lower age distribution in present study may be 
due to younger age at marriage in our society. More non-obese patients with 
BMI <27 were included in present study as compared to the study done by 
Langer et al in which more obese patients were included in the study in both 
insulin (65%) and glibenclamide (70%) group. Gestational age at entry into 
study was similar and comparable in both present study and study by Langer 
et al.
TABLE-II GLYCAEMIC STATUS DURING TREATMENT
Insulin Group Glibenclamide Group
Fasting 
Plasma 
Glucose
Postprand
ial Plasma 
Glucose
Fasting 
Plasma 
Glucose
Postprandi
al Plasma 
Glucose
Present 
Study 68.53±13.5 98.6±10.1 62.27±7.0 95.9±6.1
Langer 
et al 
Study
98.0±13.0 113±22 96.0±16.0 112.0±15.0
Adequate glycaemic control was achieved in both insulin and glibenclamide 
group in the present study and no patient was switched over to insulin 
because of poor glycaemic control. In Langer et al study except 8 patients 
(4%) who were switched over to insulin owing to poor glycaemic control 
with maximum dose of glibenclamide (20 mg) other patients attained good 
glycaemic control in both the groups. The blood sugar values of patients of 
Langer et al study given in the table was measured by them at home which 
had a strong association with the blood sugar values taken during clinic 
visits. The mean plasma glucose concentration measured during clinic visits 
was 102 +24mg /dl in glibenclamide group and 99+22mg/dl in the insulin 
group.
Pre-pregnant HbA1c in present study as compared with Langer et al study.
TABLE - III PRE-PREGNANT HbA1c
Insulin 
Group
Glibenclamid
e Group ‘P’ Value
Present Study 5.5±0.89 5.1±0.46 0.45
Langer et all 
Study 5.7±1.3 5.6±1.2 0.42
Pre –pregnant HbA1c were similar in both present study and Langer et al 
study and lie within normal range.
The neonatal outcome of present study compared with Langer et al study. 
TABLE-IV  NEONATAL OUT COME
Insulin Group Glibenclamide Group
Birth 
wt
Cord 
bloo
d 
insul
in
S
ti
ll 
bi
rt
h
Neon
atal 
death
Birth 
wt
Cord 
bloo
d 
insul
in
S
ti
ll 
bi
rt
h
Neon
atal 
death
Pre
sent 
Stu
dy
2.88±
0.45
5.24
±2.7
0 0
2.56±
0.84
4.88
±4.9
0 0
Lan
ger 
et 
al 
Stu
dy
3.19±
0.59
15.0
±2.1
1 1
3.25±
0.53
15.0
±1.3
1 1
TABLE-V  MATERNAL OUT COME
Insulin Group Glibenclamide Group
Pre-
Eclampsia Caesarian
Pre-
Eclampsia Caesarian
Present 
Study
13.3 % 66.7 % 7.7 % 69.2 %
Langer 
et al 
Study
6.0 % 24.0 % 6.0 % 23.0 %
There was no case of still birth or neonatal death in the present study 
compared to that of Langer et al one where there was one case of still birth 
and neonatal death in each insulin and glibenclamide group.There was one 
case of  macrosomia in the present study in the insulin group (6.6%) and no 
case of macrosomia in the glibenclamide group. In Langer et all study the 
incidence of macrosomia was 8% in glibenclamide group and 6% in the 
insulin group. Cord blood insulin was in normal range in both studies 
indicating absence of hyperinsulinemia.The incidence of preeclampsia was 
13.3% in insulin group  and 7.7%in glibenclamide group in present study 
compared to Langer et al study where incidence of preeclampsia was 6% in 
both groups.The cesarean section rate was 66.7%in insulin group and 69.2% 
in glibenclamide group in the present study compared to Langer et al  study 
where it was 24% and 23% respectively.
In another study by Kremer et al using glyburide for the treatment of 
gestational diabetes. 73 patients were treated with glyburide of which 59 
achieved satisfactory control (80 .8%).In the present study all patients 
achieved good glycaemic control . 19% had macrosomic infants in kremer et 
al study , in the present study there was no case of macrosomia in 
glibenclamide group. 
In another study by Hellmuth  et al study where OHA was used in 118 
patients the neonatal and maternal outcome was similar in both insulin and 
glibenclamide group as in present  study.
In another study by Lim J M , Tayob Y, O’Brien PM, Shaw RW where 33 
patients were put on glibenclamide and 21 on insulin . The maternal and 
foetal outcome were not statistically different between the two treatment 
groups in the study as in the present study.
There were only few studies using glibenclamide in GDM and therefore 
scant information on its efficacy. More studies are yet to come before its use 
in clinical practice.
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SUMMARY
• About 250 women attending the AN clinic were screened randomly for 
gestational diabetes by using 75 g OGTT and diagnosed as GDM if fasting 
plasma glucose more than or equal to 95 mg % and or postprandial plasma 
glucose more than or equal to 140 mg %.
• Based on the above criteria 35 patients were diagnosed as GDM. 5 patients 
did not give consent to get included in the study . Of the remaining, 15 
patients were put on insulin and 15 patients on glibenclamide .They were 
asked to attend diabetic clinic every 15 days for plasma sugar monitoring.
• These patients were followed throughout pregnancy and their pregnancy 
details recorded.The maternal and neonatal outcome was similar in both 
insulin and glibenclamide group except one 2nd trimester abortion in 
glibenclamide group and delivery of one macrosomic baby in the insulin 
group.There  was no case of congenital anomaly.
• Cord blood insulin and HbA1c assayed. Postdelivery plasma glucose taken 
in all cases before discharge and found to be in normal range.
                                                              CHAPTER – 8
CONCLUSION
In the study, the degree of glycaemic control and the perinatal outcomes were 
essentially the same for those treated with glibenclamide and insulin, except 
one bad outcome in glibenclamide group who had II trimester abortion 
probably due do late detection and one baby who was macrosomic (3.5 kg) in 
the Insulin group.The lack of differences between the infants born to mother 
in the two treatment groups corroborated the results in the mother.
Maternal hyperglycaemia in GDM is translated to the foetus resulting in 
foetal hyperglycaemia which is more deleterious to the foetus than the drug 
effect used in the treatment of GDM. Moreover glibenclamide does not cross 
the placenta due to its property of extensive protein binding ,short half life 
,and acting as a substrate for P-glycoprotein and inhibiting it.
Hence  the conclusion of the study is that glibenclamide may be a safe and 
efficient alternative therapy to Insulin in the treatment of GDM. Since the 
sample size is small, more studies are needed to substantiate this finding.
STUDY PROFORMA
A  GENERAL
Name :
Age : Education :
Address & Telephone No :
Date of inclusion into study :
LMP: EDD:
Gestational Age at the time of inclusion into study:
B  OBSTETRIC HISTORY
Grivida Para Abortion Stillbirth
FAMILY HISTORY
Father  Y/N : Mother  Y/N :
Siblings Y/N : 1st degree relatives  Y/N :
GE :
Anaemia  Y/N :
Pedal Edema  Y/N :
Acanthosis nigricans  Y/N :
BP :
Height : Weight
Pre-pregnancy weight :
BMI (calculated from the pre-pregnancy weight) :
C. ASSOCIATED PROBLEMS IN PREVIOUS PREGNANCIED
Pregnanc
y
Deliver
y Y/N
If no 
was it 
waste
d
Maternal complications
GDM 
/ IGT
Pre- 
Eclamsi
a
PCO
D
Endocri
ne 
disorder
s
Proteinur
ia Rx
Other 
informa-
tion
D. PREVIOUS PREGNANCIES OUTCOME :
Pregnan
cy
Date 
of 
deliver
y
Details of delivery
Normal Assisted
Caesare
an
Sex 
of 
child
Details of child
Birth 
weight
Congenital 
abnormaliti
es Y/N
Other 
complicatio
ns Y/N    If 
yes, details
E. SCREENING DATAILS
Date of Screening :
Week of gestation :
FPG :
2 Hr PPG :
OTHER INV :
Microalbuminuria :
Retinopathy :
Others :
F. TREATMENT SCHEDULE :
Visit log Date of visit Gest week Plasma glucose
Glibenclamide 
(in mg) / Insulin 
G. USG FINDINGS (include fetal abdominal circumference)
22 weeks 28 weeks 32 weeks 36 weeks
H. OUTCOME OF PRESENT PREGNANCY
Delivered :  Y/N
If no was it wasted :
If delivered :
D.O.D :
Sex of the child :
Mode of delivery : Spontaneous (   ) Induction (   ) Caesarean (   )
Weight :
Height :
Apgar :
New born Infants blood glucose :
I. MATERNAL COMPLICATIONS :
Proteinuria :  Y/N
Retinopathy :  Y/N
Others :
J. NEONATAL COMPLICATIONS :
Congential abnormality Y/N if yes specify :
Neonatal Hypoglycemia : (Y/N)
Shoulder Dystocia : (Y/N)
Any other Information :
            ABBREVIATIONS
ATP - Adenosine Triphosphate
BMI - Body Mass Index
BOH - Bad obstetric History
BP - Blood Pressure
EDD - Expected Date of Delivery
GA - Gestational Age
GDM - Gestational Diabetes Mellitus
HbA1c - Glycosylated Haemoglobin
HPL - Human placental lactogen
LMP - Last Menstrual period
NBPG - New Born plasma glucose
NDDG - National Diabetes Data Group
NICU - Neonatal intensive care unit
OGCT - Oral Glucose Challenge Test
OGTT - Oral Glucose Tolerance Test
OHA - Oral Hypoglycaemic Agents
PG - Plasma Glucose
SD - Standard deviation
USG - Ultrasonogram
WHO - World health organization
